Enhanced COVID-19 Transparency Act of 2025

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 3291 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  1st Session
                                S. 3291

 To require a declassification review for intelligence relating to the 
               COVID-19 pandemic, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                            December 1, 2025

   Mr. Young introduced the following bill; which was read twice and 
            referred to the Select Committee on Intelligence

_______________________________________________________________________

                                 A BILL


 
 To require a declassification review for intelligence relating to the 
               COVID-19 pandemic, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Enhanced COVID-19 Transparency Act 
of 2025''.

SEC. 2. DECLASSIFICATION OF INTELLIGENCE AND ADDITIONAL TRANSPARENCY 
              MEASURES RELATING TO THE COVID-19 PANDEMIC.

    (a) Definitions.--In this section, the terms ``congressional 
intelligence committees'' and ``intelligence community'' have the 
meanings given such terms in section 3 of the National Security Act of 
1947 (50 U.S.C. 3003).
    (b) In General.--Not later than 180 days after the date of the 
enactment of this Act, the Director of National Intelligence and each 
head of an element of the intelligence community shall jointly--
            (1) perform a declassification review of intelligence 
        products relating to the origins of the Coronavirus Disease 
        2019 (COVID-19), including--
                    (A) research conducted at the Wuhan Institute of 
                Virology or any other medical or scientific research 
                center within the People's Republic of China;
                    (B) information relating to Gain of Function 
                research and the intention of this research; and
                    (C) information relating to sources of funding or 
                direction for research on coronaviruses, including both 
                sources within the People's Republic of China and 
                foreign sources;
            (2) perform a declassification review of intelligence 
        products relating to efforts by government officials of 
        entities of the People's Republic of China--
                    (A) to disrupt or obstruct information sharing or 
                investigations into the origins of the coronavirus 
                disease 2019 (COVID-19) pandemic;
                    (B) to disrupt the sharing of medically significant 
                information relating to the transmissibility and 
                potential harm of SARS-CoV-2 to humans, including--
                            (i) efforts to limit the sharing of 
                        information with the United States Government;
                            (ii) efforts to limit the sharing of 
                        information with the governments of allies and 
                        partners of the United States; and
                            (iii) efforts to limit the sharing of 
                        information with the United Nations and World 
                        Health Organization;
                    (C) to obstruct or otherwise limit the sharing of 
                information between national, provincial, and city 
                governments within the People's Republic of China and 
                between subnational entities within the People's 
                Republic of China and external researchers;
                    (D) to deny the sharing of information with the 
                United States, allies and partners of the United 
                States, or multilateral organizations, including the 
                United Nations and the World Health Organization;
                    (E) to pressure or lobby foreign governments, 
                journalists, medical researchers, officials of the 
                United States Government, or officials of multilateral 
                organizations (including the United Nations and the 
                World Health Organization) with respect to the source, 
                scientific origins, transmissibility, or other 
                attributes of the SARS-CoV-2 virus or the COVID-19 
                pandemic;
                    (F) to disrupt government or private-sector efforts 
                to conduct research and development of medical 
                interventions or countermeasures for the COVID-19 
                pandemic, including vaccines; and
                    (G) to promote alternative narratives regarding the 
                origins of COVID-19 as well as the domestic Chinese and 
                international response to the COVID-19 pandemic;
            (3) make available to the public appropriately declassified 
        intelligence products described under paragraphs (1) and (2), 
        including such redactions as the Director, with the concurrence 
        of the head of the originating element of the intelligence 
        community, determines necessary to protect sources and methods 
        and information concerning United States persons; and
            (4) submit to the congressional intelligence committees an 
        unredacted version of the declassified intelligence products 
        described in paragraph (3).
                                 <all>